Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 07.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 02.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nge Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
Stammdaten
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Kura Oncology, Inc. |
|---|---|
| Ticker | KURA |
| CIK | 0001422143 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 783,9 Mio. USD |
| Beta | 0,24 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 67,482,000 | -278,666,000 | -3.18 | 738,363,000 | 174,135,000 |
| 2025-09-30 | 10-Q | 20,750,000 | -74,116,000 | -0.85 | 649,381,000 | 242,542,000 |
| 2025-06-30 | 10-Q | 15,288,000 | -66,122,000 | -0.75 | 682,425,000 | 305,486,000 |
| 2025-03-31 | 10-Q | 14,108,000 | -57,429,000 | -0.66 | 743,764,000 | 364,406,000 |
| 2024-12-31 | 10-K | 53,883,000 | -173,983,000 | -2.02 | 760,159,000 | 413,640,000 |
| 2024-09-30 | 10-Q | -54,404,000 | -0.63 | 478,837,000 | 423,771,000 | |
| 2024-06-30 | 10-Q | -50,837,000 | -0.59 | 515,116,000 | 466,070,000 | |
| 2024-03-31 | 10-Q | -49,525,000 | -0.59 | 553,908,000 | 505,084,000 | |
| 2023-12-31 | 10-K | 0 | -152,631,000 | -2.08 | 448,935,000 | 397,273,000 |
| 2023-09-30 | 10-Q | -38,602,000 | -0.50 | 473,771,000 | 429,937,000 | |
| 2023-06-30 | 10-Q | -37,174,000 | -0.53 | 494,737,000 | 459,678,000 | |
| 2023-03-31 | 10-Q | -34,069,000 | -0.50 | 425,975,000 | 395,183,000 | |
| 2022-12-31 | 10-K | -135,840,000 | -2.03 | 456,306,000 | 420,278,000 | |
| 2022-09-30 | 10-Q | -35,504,000 | -0.53 | 447,988,000 | 419,621,000 | |
| 2022-06-30 | 10-Q | -34,769,000 | -0.52 | 471,425,000 | 449,491,000 | |
| 2022-03-31 | 10-Q | -32,453,000 | -0.49 | 498,585,000 | 476,250,000 | |
| 2021-12-31 | 10-K | -130,466,000 | -1.97 | 534,051,000 | 506,609,000 | |
| 2021-09-30 | 10-Q | -33,366,000 | -0.50 | 561,141,000 | 533,756,000 | |
| 2021-06-30 | 10-Q | -33,663,000 | -0.51 | 584,891,000 | 558,551,000 | |
| 2021-03-31 | 10-Q | -30,694,000 | 620,263,000 | 585,987,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-27 | Powl Brian T. | Officer, Chief Commercial Officer | Open Market Sale | -1,572 | 8.46 | -13,300.22 | -8,7% | |
| 2026-01-27 | Powl Brian T. | Officer, Chief Commercial Officer | Open Market Sale | -4,842 | 8.46 | -40,966.23 | -26,6% | |
| 2025-12-09 | Hasnain Faheem | Director | Open Market Sale | -10,000 | 10.98 | -109,764.00 | -71,4% | |
| 2025-11-14 | Powl Brian T. | Officer, Chief Commercial Officer | Open Market Sale | -8,887 | 11.18 | -99,329.11 | -64,6% | |
| 2025-09-29 | WILSON TROY EDWARD | Director, Officer, President and CEO | Open Market Sale | -36,615 | 8.94 | -327,418.65 | -213,0% | |
| 2025-09-29 | Powl Brian T. | Officer, Chief Commercial Officer | Open Market Sale | -8,891 | 8.94 | -79,505.10 | -51,7% | |
| 2025-09-08 | WILSON TROY EDWARD | Director, Officer, President & CEO | Open Market Purchase | 50,000 | 8.20 | 410,145.00 | +266,8% | |
| 2025-08-13 | WILSON TROY EDWARD | Director, Officer, President and CEO | Open Market Purchase | 13,494 | 6.64 | 89,623.10 | +58,3% | |
| 2025-08-12 | WILSON TROY EDWARD | Director, Officer, President and CEO | Open Market Purchase | 36,506 | 5.85 | 213,578.35 | +138,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.